Although treatment to reduce GH and IGF-1 levels can decrease risk of cardiac hypertrophy and arrhythmias, as well as improve diastolic function [70], improvements in systolic function and response to exercise depend mostly on disease duration and the presence of hypertension and diabetes [63]. This evidence concerns the gene IGF1 and cardiac arrhythmia.